BioCentury

10:39 PM GMT, Mar 29, 2019
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

ORI goes oncolytic

Oncolytic virus company Cold Genesys continues to draw East Asian investors on the back of its data in bladder cancer.

ORI Healthcare Fund L.P.'s Simone Song said the Hong Kong fund had been following Cold Genesys Inc. since 2015 and was impressed

Read the full 415 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.